SOLTF (Nxera Pharma Co) Total Equity: $401.3 Mil (As of Mar. 2026)


SOLTF Nxera Pharma Co Ltd SOLTF
84 GF Score
Price $6.37
GF Value $8.74
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co Total Equity?

Nxera Pharma Co SOLTF 84 Total Equity is $401.3 Mil as of Mar. 2026. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $8.74 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Nxera Pharma Co's total equity for the quarter that ended in Mar. 2026 was $401.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nxera Pharma Co Total Equity Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Total Equity Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 504.85 429.43 464.02 445.46 391.22

Nxera Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 449.97 455.84 444.03 391.22 401.34
SOLTF
84GF Score
Nxera Pharma Co Ltd SOLTF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nxera Pharma Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=864.49-473.271
=391.2

Nxera Pharma Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=840.281-438.939
=401.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $401.3 Mil mean?
Nxera Pharma Co (SOLTF) has a Total Equity of $401.3 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's Total Equity too high?
Nxera Pharma Co's current Total Equity is $401.3 Mil. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Total Equity compare to VRTX and REGN?
Nxera Pharma Co's Total Equity of $401.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nxera Pharma Co and its competitors. Nxera Pharma Co's current Total Equity is $401.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.74, compared to a current price of $6.37 — trading 27.1% below its estimated fair value. The current Total Equity is $401.3 Mil. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current Total Equity is $401.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (SOLTF) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of $6.37 is trading 27.1% below its estimated GF Value™ of $8.74. GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.

Key valuation signals for SOLTF:

  • Total Equity: $401.3 Mil
  • GF Value™: $8.74 vs. price of $6.37 (27.1% below fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Other Exchanges 4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
84GF Score

Get the complete analysis for SOLTF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.37
Price
$8.74
GF Value